English Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil

Revista de Ciencias Biomédicas

  • ISSN: 2254-609X
  • Índice h de la revista: 15
  • Puntuación de cita de revista: 5.60
  • Factor de impacto de la revista: 4.85
Indexado en
  • Genamics JournalSeek
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Directorio de indexación de revistas de investigación (DRJI)
  • OCLC-WorldCat
  • Google Académico
  • SHERPA ROMEO
  • Laboratorios secretos de motores de búsqueda
Ver más
Comparte esta página

Abstracto

Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance

Dae Won Kim, Marc Uemura and Adi Diab

Since pembrolizumab (Keytruda®) was approved for advanced melanoma in September 2014, multiple PD-1 blockade agents have been explored in other malignancies. Emerging clinical data has demonstrated durable clinical activity and safety of PD-1/L1 blockade agents in diverse cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, and head and neck cancer. Thus, PD-1/L1 blockade agents have led to a paradigm shift in cancer therapy. In this review, current indications of PD-1 blockade agents in advanced solid malignancies will be discussed.